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Introduction
A large increase in both diagnostic and therapeutic interventional 
procedures has been observed in recent years [3,4]; the most common 
of them being coronary angiography (CA) and percutaneous coronary 
intervention (PCI) [4,5]. Cardiac conditions previously treated by 
open heart surgery may now be safely and effectively performed by 
x-ray-guided interventions [6]. However, advances in technology have 
allowed complex cases to be treated leading to longer fluoroscopy 
times and thus to higher levels of radiation exposure [6,7]. Exposure 
to x-ray radiation has been demonstrated to increase the risk of 
cancer [2,8]. Thus, the use of radiation in medicine is only accepted 
when the benefits are greater than the associated risks [2]. Therefore, 
every procedure that involves exposure to ionizing radiation has 
to be justified. Before prescribing or performing a radiological 
procedure for any individual patient, the physician has to weigh the 
benefits with the risks taking into account the suspected pathology, 
the characteristics of the patient, alternative medical procedures, 
etc. The risk-benefit analysis is particularly important for high-dose 
procedures, such as interventional radiology. Risk assessment is a 
critical part of the justification process and pertinent quantities have 
to be used to perform such an evaluation. In addition, radiological 
procedures need to be optimized on the basis of reliable indicators.
The effective dose (E) as defined by International Commission 
on Radiological Protection (ICRP) is based on the use of equivalent 
doses, i.e. mean tissue and organ absorbed doses each weighted by 
radiation weighting factors which take account of the differences in 
radio-biological effectiveness of various radiations. Effective dose is 
the sum of all organ and tissue equivalent doses each weighted by 
specific tissue weighting factors which are intended to take account 
of the differences in sensitivity of tissue and organs with respect to 
stochastic effects. The aim of the E was to define a radiation protection 
quantity is which is related to the probability of a detriment from low-
dose exposure to ionizing radiation where only stochastic effects occur 
and which is suited for setting exposure limits and for implementing 
the optimization principle in the context of occupational and public 
exposure. The concept of E was adopted by the ICRP 26 (1977) [9] 
and further developed in its recommendations ICRP 60 (1991) and 
103 (2007) [1,2]. E was initially proposed for the radiation protection 
of the occupational workers and the general public. However, the 
convenience and ease of evaluating E in given exposure situations as 
well as the lack of established methods to estimate patient risks has 
led to its widespread use in the estimation of patient risks [10]. Yet, 
publications on awareness of the physicians on radiation protection 
show that radiation risks are not well understood and assessed [11-
15]. Moreover, it seems that the language of radiation protection is 
confusing for non-specialists, for instance the use of Sv as unit of both 
the equivalent organ dose and the effective dose [16,17]. Therefore, 
there is a need for a quantity that is more dedicated to the assessment 
of radiation risks, and comprehensive by non-specialists. Equivalent 
organ dose was intended to quantify the organ risk to assess a certain 
detriment by multiplying the dose to the organ by the respective risk 
coefficient [18]. Brenner [16] proposed the use of cancer incidence 
risks for different organs and tissues provided in the Biological Effects 
of Ionizing Radiations (BEIR) report VII (NRC 2006) [8] and the 
estimation of the effective risk (R) [9]. 
The objective of our study was to examine the possible use of R 
as an estimate of radiation risk during common cardiac procedures. 
To this purpose, two typical cardiac interventional procedures were 
simulated and the corresponding organ doses and potential risks for 
cancer induction were estimated.
Materials and Methods
Patient study
Patient data were derived from the database of a cardiology 
department. For our study, data for all the patients referred to CA 
and PCI procedures during one year were exported. Patient data 
included patient demographics (sex, weight, height, body mass 
index (BMI) and age), volume of the contrast agent as well as dose 
parameters, such as kerma-area product (KAP), fluoroscopy time (T) 
and cumulative dose (CD) measured at the interventional reference 
point. The number of images obtained during a procedure was not 
automatically registered and thus, not included in the database. 
Patients were divided into different categories according to their BMI 
(the weight (kg) of the patient divided by the square of the height 
(m2)). No patients with a BMI less than 18.5 undergoing a CA or PCI 
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procedure were found. In this study, only data of normal patients were 
taken into account in order to describe a typical procedure for an 
average patient. Independent samples Student t-tests were performed 
to test any differences between a) male and female patients and b) CA 
and PCI procedures. The statistical analysis was performed with the 
SPSS software (version 18, SPSS Inc. Chicago, IL).
During a four-month period, a detailed study was performed 
for the patients referred to CA and PCI procedures. The sample 
included 32 male and 15 female patients. For these patients technical 
and physical parameters were recorded, such as source-to-detector 
distance, number of images acquired during the procedure, tube 
angulation, and tube voltage (kV) for each series of images. All 
procedures were performed with a monoplane X-ray unit (Allura 
Xper FD10, Philips Healthcare, Philips, Eindhoven, Netherlands) 
equipped with a dynamic flat-panel detector. Pulsed fluoroscopy and 
cineangiography were used during the procedures. 
Monte Carlo simulations
To estimate organ doses during coronary procedures, Monte 
Carlo simulations were performed. Monte Carlo simulations are 
widely used to estimate the radiation dose distribution in the body 
[19-22]. The general-purpose radiation transport code MCNPX 
was employed (version 2.5.0, Los Alamos National Laboratory, Los 
Alamos, NM). This code can handle the transport and interactions 
of photons, electrons, neutrons and other particles for a wide range of 
energies and is three-dimensional and time-dependent. 
The simulation of the human body was performed using the 
ICRP 110 voxelized adult reference phantoms [23]. The two phantoms 
are the official computational models representing the Reference 
Male and Female. The models are based on computed tomography 
images of real individuals and represent the human anatomy in three 
dimensions. The voxel volume for the Reference Male was 36.54 
mm3 and that for the Reference Female 15.25 mm3. The phantoms 
represent an adult male of 73 kg weight and 1.76 m height and an 
adult female of 60 kg and 1.63 m. All the organs and tissues required 
for the calculation of the effective dose according to ICRP 103 [2] are 
included in the phantoms. 
Three x-ray spectra (70,80 and 90 kVp) and 3 mm Al total 
filtration were produced according to the method developed by Boone 
and Seibert [24]. The distance of the x-ray tube to the detector was 
assumed to be constant at 100 cm. Five main projections (posterior 
anterior (PA), right anterior oblique 30° (RAO30°), left lateral (LLAT), 
left anterior oblique 10° (LAO10°), and left anterior oblique 60o 
(LAO60°) and three additional ones (right anterior oblique 30° and 
caudal 20° (RAO30°CAD20°), left anterior oblique 10° and cranial 
10° (LAO10°/CRA10°), and left anterior oblique 60° and cranial 10° 
(LAO60°/CRA10°) were studied. For all tube angulations, the field of 
view was chosen to be 10x10 cm2 centred at the heart of the patient. 
In all simulations, 200 million histories were performed to ensure 
that the statistical error was acceptable. Typical CPU time for the 
simulations varied between 11 and 20 hours on a nine-PC cluster (HP 
3646/3GHz/dual core/4Gb RAM, Linux 2.6.32-35-generic, Ubuntu 
10.04), depending on the source geometry and energy spectrum.
Verification measurements
To verify the Monte Carlo results, a physical anthropomorphic 
phantom (Model 702-D, ATOM, CIRS, Norfolk, VA) that simulates 
the body trunk of an adult female 1.60 m in height and 55 kg in weight 
was used. The phantom is sectional in design with thirty-eight 25-mm-
thick slabs of tissue equivalent material. The tissue-equivalent epoxy 
resins simulate soft tissue, skeleton and lungs and allow the phantom’s 
use for radiation energies in the field of diagnostic radiology. The 
phantom provides thermo-luminescent dosimeters (TLDs) locations 
specific to 21 inner organs. Eighty TLDs were loaded in the phantom in 
different organs to measure the absorbed dose. The same geometrical 
setup with that of Monte Carlo simulations was followed to verify 
the Monte Carlo results. The phantom was exposed to 50 Gy∙cm2 to 
reduce the statistical errors of the TLD measurements. Normalized 
organ dose values were calculated as the mean dose gauged by TLDs 
divided by the total KAP for each exposure. Data derived by using TLD 
dosimetry were compared with corresponding data derived from 
Monte Carlo simulations.
The TLD crystals (LiF:Mg,Tl chips, TLD-100; Harshaw, Solon, 
Ohio) were calibrated towards an ionization chamber NE 2575 600 
cm3 (Nuclear Enterprise, U.K.) connected to an electrometer Keithley 
6517A (Keithley Instruments Inc, Cleveland, Ohio) and a Co-60 
source (mean energy 1.25 MeV). The individual sensitivity of each 
TLD was determined taking into account the energy correction factor 
calculated by mass energy absorption coefficients. Thus, the overall 
uncertainty of TLD measurements was lower than 5%. The TLD 
reading was performed by a Harshaw 5500 reader system (Harshaw, 
Solon, Ohio). The annealing process for the TLDs was carried out at 
a determined oven Hengstler grado 921 (Hengstler GmbH, Aldingen, 
Germany) for an annealing cycle at 385°C for 75 minutes followed by 
another annealing cycle at 100°C for 135 min in the oven Venticell 
222 (MMM Medcenter Einrichtungen GmbH, Munich, Germany). 
The first annealing cycle is performed for the re-crystallization of the 
TLDs while the second one is performed to erase the first two peaks of 
the thermo-luminescent signal, which reduce the dosimeter “fading”. 
Estimation of effective dose
The energy deposition to the organs and tissues was estimated 
using the *f8-type tally (in MeV). This is a pulse height tally. It is 
defined by the energy entering a cell (in our case each cell was an organ 
or tissue) minus the energy leaving this cell for the entire history for 
each particle emitted by the source. The amount of energy deposited in 
a cell is the pulse height for that history. A full pulse height spectrum 
is created when the distribution of the energy deposited by all incident 
source particles is recorded. The pulse height tally requires the entire 
set of tracks for a history to be completed. The absorbed dose in the 
organ or tissue (DT) was calculated by the energy deposited in the 
organ or tissue over the corresponding mass (MeV/kg). KAP was also 
calculated by multiplying the free-in-air-kerma value with the area of 
the x-ray field. The KAP-normalized organ dose (DTKAP) was calculated 
by the value of the organ dose divided by the KAP, as summarized in 
the equation:
 KAP T
T
DD KAP=
                  (1)
The KAP-normalized equivalent dose (HTKAP) in an organ or tissue 
was calculated by:
  
,
KAP KAP
T R T R
R
H w D= ⋅∑                  (2)
Where the wR is the radiation weighting factor for radiation R, in 
our case, the radiation weighting factor for the photons was 1.
E is based on the mean equivalent doses in organs or tissues of 
the human body. The tissue weighting factors represent average 
values for individuals of both sexes. Thus, the equivalent doses in the 
organs and tissues of the Reference Male and the Reference Female 
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were averaged. The averaged equivalent doses were then multiplied 
with the corresponding tissue weighting factor. The KAP-normalized 
effective dose (EKAP) was calculated as following:
 
, ,
, 2
KAP KAP
KAP KAP T Male T Female
breast breast Female T
T breast
H HE w H w
≠
 +
= ⋅ + ⋅  
  
∑          (3)
Where the summation includes the gonads dose (testes in the 
male and ovaries in the female)
The tissue weighting factors wT are given in table 1. E was calculated 
using both ICRP 60 and 103 [1,2]. The new recommendations define 
the colon and the remainder tissues differently from the old ones and 
this was also taken into account in the E calculations.
Estimation of effective risk 
The term “effective risk” R was proposed by [16] in order to 
estimate the cancer risk from a radiological procedure. R may be 
calculated as following:
         
  T T
T
R r D= ⋅∑                                                   (4)
where rT is the lifetime radiation-attributable tissue- specific 
cancer risks, as defined by BEIR VII (NRC 2006) [8] and DT is the 
equivalent dose in tissue T. The unit of R is the cancer incidence. Table 
2 shows the risk for cancer incidence according to BEIR VII. The risks 
are age- and sex-dependent. The dose to “other” (Dother) was calculated 
as following:
                  T T
T
other
T
T
w D
D w
⋅
=
∑
∑
                
(5)
Where DT is the mean organ dose for a typical cardiac procedure, 
wT is the tissue weighting factors for the corresponding organs 
according to ICRP 103 [2]. T concerns the oesophagus, brain, bone 
surface, skin, salivary glands, the gonads (for male calculations), 
and the remainder tissue mentioned in ICRP 103 [2] except for the 
prostate and the uterus. 
Results & Discussion
Patient characteristics 
In total, 269 patients were included in the study. In table 3, patient 
demographics, i.e. age, weight, height and BMI, are presented for 
CA and PCI procedures. Of the 137 patients who underwent a CA 
procedure, 76 were males and 61 were females with a mean age of 67 
years and mean BMI of 22.7 kg/m2. The 136 patients that underwent 
PCI procedure were 91 males and 41 females with mean age of 67 
years and mean BMI 23.1 kg/m2. 
The parameters related to the patient dose, i.e. KAP, fluoroscopy 
time, etc are presented in table 4 and 5 for the CA and PCI procedures, 
respectively. The mean values for exposure (KAP, T, number of images, 
CD) during CA procedures were found significantly lower than those 
for PCI procedures (p-values < 0.001). The number of images acquired 
during the procedures was determined by the sample patient study. 
This study showed also that the mean tube voltage applied was 77 and 
83 kV for CA and PCI procedures, respectively.
Equivalent organ dose
KAP-normalized doses for the all organs and tissues recommended 
by the ICRP were estimated. Tables 6 and 7 present the KAP-normalized 
doses for the main organs and the remainder organs and tissues as 
defined by both ICRP 60 and 103 [1,2]. The heart is included in the 
remainder organs in ICRP 103; however, we decided to also provide 
separately the dose to the heart as it is the target organ during the 
procedures studied. 
The KAP-normalized doses for the colon were calculated with both 
ICRP 60 and 103 [1,2] and were found to differ in average by 36 times. 
Organ/Tissue ICRP 60 ICRP 103
Gonads 0.20 0.08
Colon 0.12 0.12
Lungs 0.12 0.12
Red bone marrow 0.12 0.12
Stomach 0.12 0.12
Bladder 0.05 0.04
Breast 0.05 0.12
Liver 0.05 0.04
Oesophagus 0.05 0.04
Thyroid 0.05 0.04
Bone surface 0.01 0.01
Skin 0.01 0.01
Brain 0.01
Salivary glands 0.01
Remainder 0.05a 0.01b
aICRP 60 remainder organs/tissues: adrenals, brain, kidneys, muscle, pancreas, 
small intestine, large intestine, spleen, thymus, uterus
bICRP 103 remainder organs/tissues: adrenals, extrathoracic tissue, gall bladder, 
heart, kidneys, lymphatic nodes, muscle, oral mucosa, pancreas, prostate, small 
intestine, spleen, thymus, uterus/cervix
Table 1: Tissue weighting factors wT according to ICRP 60 and 103.
Age at exposure (y)
Cancer site 30 40 50 60 70 80
Male
Stomach 28 27 25 20 14 7
Colon 125 122 113 94 65 30
Liver 22 21 19 14 8 3
Lung 105 104 101 89 65 34
Prostate 35 35 33 26 14 5
Bladder 79 79 76 66 47 23
Other 198 172 140 98 57 23
Thyroid 9 3 1 0,3 0,1 0
All solid 602 564 507 407 270 126
Leukaemia 84 84 84 82 73 48
All cancers 686 648 591 489 343 174
Female
Stomach 36 35 32 27 19 11
Colon 82 79 73 62 45 23
Liver 10 10 9 7 5 2
Lung 242 240 230 201 147 77
Breast 253 141 70 31 12 4
Uterus 18 16 13 9 5 2
Ovary 34 31 25 18 11 5
Bladder 79 78 74 64 47 24
Other 207 181 148 109 68 30
Thyroid 41 14 4 1 0,3 0
All solid 1002 824 678 529 358 177
Leukaemia 63 62 62 57 51 37
All cancers 1065 886 740 586 409 214
Table 2: Lifetime attributable risk of cancer incidence according to BEIR VII per 
100,000 persons exposed to a single dose of 0.1 Gy.
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This was expected as the colon according to ICRP 60 was defined 
as the lower large intestine, but according to ICRP 103 the colon 
includes also the upper large intestine. The difference in the doses of 
the remainder tissue was less noticeable. In ICRP 60, the remainder 
tissue included 10 organs and tissues, while in ICRP 103 by 14 organs 
(13 for each sex). 
The dependence of the organ dose on the tube voltage is presented 
in figure 1 for the LAO10° projection. As expected, the higher the 
tube voltage, the higher the dose. Organs that are inside the x-ray 
field have higher KAP-normalized doses, as for example the lungs, 
the oesophagus and the heart in figure 1. In contrast, organs that lie 
outside the x-ray field, such as the thyroid, receive lower doses. In 
average the KAP-normalized doses differ by 1.8 times for tube voltages 
between 70 and 90 kVp. The higher differences (up to 6 times) were 
observed for low KAP-normalized doses, such as the case of gonads for 
RAO projection. Organs with low KAP-normalized doses are exposed 
to scatter radiation; thus, their exposure highly depends on the energy 
of the scatter radiation.
The KAP-normalized doses for three tube angulations RAO30°, 
LAO10° and LAO60° were compared to the RAO30°CAD20°, 
LAO10°/CRA10°, and LAO60°/CRA10°. A tilt of 10 to 20 degrees in 
the sagittal plane led to a mean difference of 15% in organ doses. 
As expected, the difference in organ doses increases with the angle 
increase, for instance 30% difference in the heart dose for RAO30° 
and RAO30°CAD20°. 
A typical cardiac procedure may be described by the five main 
projections (PA, RAO30°, LAO10°, LAO60° and LLAT) for 80 kVp. The 
KAP-normalized doses for the organs and tissues for these angulations 
were averaged and multiplied by the mean KAP values for the CA 
and PCI procedures. The mean organ doses are presented in table 
6. During a typical cardiac intervention, the most irradiated organs 
were found to be the lungs, heart, red bone marrow, oesophagus and 
breast, as illustrated in figure 2. Stomach and liver may also receive 
high doses. A special remark has to be made for the skin dose. The 
skin dose provided in tables 6-8 concerns the total skin and may be 
used only for the estimation of the effective dose. In real practice, only 
a small portion of the skin is directly irradiated at the body entrance. 
Moreover, skin areas may be irradiated by overlapping x-ray fields and 
may lead even to skin burns [25]. A quite good indicator for the skin 
dose is the CD at the interventional reference point, which is provided 
in modern x-ray units [26]. 
KAP-normalized organ doses were also provided in previous [27-
29]. An extensive study in cardiac interventional procedures was 
performed in 1995 by Stern et al. [29]. Schlattl et al. [28] simulated the 
voxel phantoms Regina and Rex which were then adopted by the ICRP 
as the Reference Male and Female phantoms. However, differences in 
the phantom used by Stern et al [29] as well as the tube filtration and 
voltage, used by [28], do not allow a meaningful comparison between 
the results. A comparison was possible with the results of Bozkurt and 
Bor [27] for the male phantom KAP-normalized organ dose. In this 
CA PCI
Number of patients 137 132
Age (y) 67 ± 14 (32-93) 67 ± 12 (35-87)
Sex 76 M / 61 F 91 M / 41 F
Weight (kg) 65 ± 10 (47-97) 67 ± 9 (49-90)
Height (m) 1.7 ± 0.9 (1.5-2.0) 1.7 ± 0.8 (1.5-1.9)
BMI (kg/m2) 22.7 ± 1.8 (18.8-25) 23.1 ± 1.6 (18.7-25)
Contrast volume (ml) 85.3 ± 43.1 (10-320) 173.7 ± 56.7 (50-350)
Table 3: Patient demographics for CA and PCI procedures.
Mean Standard 
deviation
Range 25th 
percentile
50th 
percentile
75th 
percentile
KAP (Gy∙cm
2) 36.7 53.4 2.0-396 14.0 24.6 38.2
T (min) 5.6 4.3 1.0-22 2.5 4.4 7.4
Number of 
imagesa
718 279 303-1,374 508 647 843
CD (mGy) 412 295 18-2,000 204 344 545
a Sample study
Table 4: Dose parameters for CA procedures.
Mean Standard 
deviation
Range 25th 
percentile
50th 
percentile
75th 
percentile
KAP (Gy∙cm
2) 65.3 43.4 9.6-271 36.2 54.6 81.3
T (min) 12.8 8.6 2.2-63 6.5 10.7 16.3
Number of 
imagesa
1,558 834 183-3,196 978 1,618 2,223
CD (mGy) 1,059 725 118-4,813 558 923 1,374
a Sample study 
Table 5: Dose parameters for PCI procedures.
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Figure 1: Dependence of eight KAP-normalized organ doses on the tube volt-
age for LAO10° projection.
Lungs: 17%
Bone marrow (red): 11%
Heart: 10%
Breast: 9%
Oesophagus: 8%
Skin: 6%
Liver: 1%
All others: 37%
Figure 2: Most irradiated organ and tissues during a typical cardiac procedure.
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publication, the voxel VIP-Man phantom was used and simulations 
were performed for tube voltage from 60 to 120 kVp and a 3.5 mm Al 
filtration. Our results are in a quite good agreement with the results 
of Bozkurt and Bor [27]. For example, the lung KAP-normalized dose 
for RAO30° projection at 70 kVp in this study was equal to 0.561 
mSv/Gy∙cm2 and the corresponding value in the Bozkurt and Bor’s 
[27] work was 0.458 mSv/Gy∙cm2. Differences may be attributed to 
different phantoms and spectrum quality.
Coefficient of variance for large volume organs and organs within 
the x-ray field, such as liver, lung, skin, heart, etc., was below 0.01%. 
Although 200 million histories were carried out for each simulation to 
reduce the statistical errors, coefficients of variance of certain organs 
remained above 50%, for example left ovary 53% for 80 kVp. 
Effective dose
The KAP-normalized effective doses according to ICRP 60 (1991) 
and ICRP 103 (2007) [1,2] for cardiac interventional procedures were 
calculated and are presented in table 9. The effective doses were found 
to be higher when using the ICRP 103 than when using ICRP 60. The 
last column in table 9 shows the ratio of the effective doses between 
ICRP 103 and ICRP 60. The differences were up to 20% and were most 
significant for the tube angulation LAO60°. In the case of cardiac 
procedures, this is attributed to the breast weighting factor, which was 
0.05 in the ICRP 60 and increased to 0.12 in the new recommendations.
Our KAP-normalized effective doses according to ICRP 60 were 
found quite lower than published ones (range from 0.09 to 0.24 mSv/
PA RAO30 RAO30/CAD20 LLAT
70 kVp 80 kVp 90 kVp 70 kVp 80 kVp 90 kVp 70 kVp 80 kVp 90 kVp 70 kVp 80 kVp 90 kVp
Brain 1.78E-04 2.81E-04 3.97E-04 1.79E-04 2.84E-04 4.10E-04 3.31E-04 4.98E-04 6.87E-04 2.48E-04 3.88E-04 5.43E-04
Breast 1.73E-01 2.29E-01 2.86E-01 1.63E-01 2.21E-01 2.79E-01 1.38E-01 1.90E-01 2.43E-01 4.29E-01 4.96E-01 5.62E-01
Bone marrow 
(red)
2.78E-01 3.40E-01 3.98E-01 8.62E-02 1.07E-01 1.32E-01 9.77E-02 1.24E-01 1.49E-01 5.90E-01 6.96E-01 8.00E-01
Bone surface 1.13E-03 1.28E-03 1.42E-03 1.04E-03 1.17E-03 1.30E-03 1.21E-03 1.36E-03 1.49E-03 8.43E-04 9.71E-04 1.09E-03
Colon 60a 1.07E-04 1.33E-04 1.80E-04 1.03E-04 1.52E-04 2.12E-04 7.04E-05 1.07E-04 1.75E-04 3.61E-05 6.77E-05 1.07E-04
Colon 103b 3.34E-03 5.35E-03 7.47E-03 4.32E-03 6.78E-03 9.39E-03 2.74E-03 4.44E-03 6.37E-03 3.67E-03 5.59E-03 7.81E-03
Oesophagus 2.39E-01 3.04E-01 3.67E-01 2.93E-01 3.58E-01 4.19E-01 2.70E-01 3.32E-01 3.92E-01 5.19E-02 6.98E-02 8.79E-02
Gonads 3.77E-05 1.83E-04 2.14E-04 2.70E-05 1.38E-04 1.67E-04 3.94E-05 7.48E-05 1.02E-04 1.28E-04 1.31E-04 1.73E-04
Liver 1.56E-02 2.22E-02 2.88E-02 1.30E-02 1.86E-02 2.43E-02 1.03E-02 1.52E-02 2.01E-02 3.50E-02 4.51E-02 5.49E-02
Lung 4.01E-01 4.80E-01 5.56E-01 5.61E-01 6.59E-01 7.53E-01 4.45E-01 5.37E-01 6.25E-01 4.15E-01 4.92E-01 5.66E-01
Salivary glands 3.03E-03 4.64E-03 6.25E-03 3.28E-03 4.86E-03 6.80E-03 4.04E-03 6.12E-03 8.14E-03 4.43E-03 6.21E-03 7.96E-03
Skin 8.94E-02 9.39E-02 9.96E-02 1.02E-01 1.07E-01 1.13E-01 1.03E-01 1.08E-01 1.14E-01 2.35E-01 2.46E-01 2.60E-01
Stomach 1.43E-02 1.98E-02 2.54E-02 2.09E-02 2.78E-02 3.47E-02 1.12E-02 1.60E-02 2.09E-02 6.28E-03 9.13E-03 1.21E-02
Thyroid 1.60E-02 2.27E-02 2.92E-02 1.79E-02 2.48E-02 3.14E-02 2.36E-02 3.22E-02 4.08E-02 1.05E-02 1.49E-02 1.94E-02
Urinary Bladder 2.14E-05 3.80E-05 5.35E-05 2.28E-05 2.77E-05 5.70E-05 1.71E-05 2.61E-05 4.54E-05 2.71E-05 5.58E-05 6.15E-05
Remainder 60a 2.27E-01 2.95E-01 3.66E-01 2.69E-01 3.47E-01 4.23E-01 2.16E-01 2.78E-01 3.43E-01 2.91E-01 3.48E-01 4.07E-01
Remainder 103b 9.67E-01 1.20E+00 1.44E+00 9.74E-01 1.21E+00 1.44E+00 8.29E-01 1.04E+00 1.26E+00 6.93E-01 8.52E-01 1.01E+00
Heart 2.89E-01 3.58E-01 4.24E-01 3.22E-01 3.93E-01 4.62E-01 2.45E-01 3.07E-01 3.66E-01 1.55E-01 1.92E-01 2.28E-01
a Calculation according to ICRP 60, b Calculation according to ICRP 103
Table 6: KAP-normalized equivalent dose (mSv/Gy∙cm2) as a function of tube voltage and angulations during cardiac interventional procedures.
LAO10 LAO10/CRA10 LAO60 LAO60/CRA20
70 kVp 80 kVp 90 kVp 70 kVp 80 kVp 90 kVp 70 kVp 80 kVp 90 kVp 70 kVp 80 kVp 90 kVp
Brain 1.77E-04 2.79E-04 4.01E-04 1.59E-04 2.55E-04 3.62E-04 2.16E-04 3.33E-04 4.67E-04 1.05E-04 1.74E-04 2.52E-04
Breast 1.71E-01 2.28E-01 2.85E-01 1.60E-01 2.14E-01 2.69E-01 7.31E-02 1.03E-01 1.33E-01 6.61E-02 9.14E-02 1.17E-01
Bone marrow (red) 3.09E-01 3.73E-01 4.34E-01 3.16E-01 3.81E-01 4.43E-01 6.52E-02 8.63E-02 1.07E-01 4.21E-02 5.76E-02 7.35E-02
Bone surface 1.15E-03 1.30E-03 1.45E-03 1.16E-03 1.31E-03 1.46E-03 7.04E-04 8.19E-04 9.25E-04 5.86E-04 6.88E-04 7.83E-04
Colon 60a 9.86E-05 1.43E-04 1.95E-04 1.16E-04 1.66E-04 2.13E-04 9.92E-05 1.28E-04 1.86E-04 1.64E-04 2.47E-04 3.23E-04
Colon 103b 3.05E-03 4.93E-03 7.07E-03 3.23E-03 5.26E-03 7.40E-03 2.01E-03 3.32E-03 4.74E-03 4.77E-03 7.25E-03 9.88E-03
Oesophagus 2.06E-01 2.67E-01 3.26E-01 2.02E-01 2.63E-01 3.23E-01 7.53E-02 1.02E-01 1.28E-01 1.02E-01 1.33E-01 1.65E-01
Gonads 1.31E-04 1.19E-04 2.20E-04 1.10E-04 1.96E-04 1.92E-04 6.69E-05 1.70E-04 2.54E-04 1.76E-04 2.46E-04 4.05E-04
Liver 1.81E-02 2.51E-02 3.22E-02 1.98E-02 2.73E-02 3.49E-02 2.12E-02 2.87E-02 3.62E-02 8.01E-02 9.83E-02 1.16E-01
Lung 3.80E-01 4.58E-01 5.34E-01 3.76E-01 4.53E-01 5.28E-01 2.63E-01 3.28E-01 3.92E-01 3.17E-01 3.84E-01 4.48E-01
Salivary glands 2.96E-03 4.44E-03 6.10E-03 2.74E-03 4.29E-03 5.82E-03 2.36E-03 3.56E-03 4.83E-03 1.74E-03 2.73E-03 3.77E-03
Skin 9.05E-02 9.50E-02 1.01E-01 9.07E-02 9.51E-02 1.01E-01 2.34E-01 2.44E-01 2.56E-01 2.62E-01 2.73E-01 2.87E-01
Stomach 1.18E-02 1.68E-02 2.19E-02 1.27E-02 1.79E-02 2.33E-02 4.01E-03 6.16E-03 8.47E-03 5.03E-03 7.58E-03 1.03E-02
Thyroid 1.55E-02 2.18E-02 2.84E-02 1.43E-02 2.03E-02 2.62E-02 9.86E-03 1.42E-02 1.86E-02 8.60E-03 1.21E-02 1.59E-02
Urinary Bladder 2.41E-05 3.78E-05 5.06E-05 1.45E-05 4.21E-05 6.58E-05 2.06E-05 3.33E-05 5.06E-05 3.76E-05 7.41E-05 1.06E-04
Remainder 60a 2.15E-01 2.80E-01 3.48E-01 2.22E-01 2.88E-01 3.59E-01 2.16E-01 2.64E-01 3.15E-01 3.03E-01 3.73E-01 4.45E-01
Remainder 103b 9.24E-01 1.15E+00 1.38E+00 9.10E-01 1.14E+00 1.37E+00 5.15E-01 6.48E-01 7.82E-01 6.46E-01 8.04E-01 9.62E-01
Heart 2.58E-01 3.22E-01 3.85E-01 2.55E-01 3.19E-01 3.82E-01 8.07E-02 1.07E-01 1.34E-01 9.35E-02 1.22E-01 1.50E-01
a Calculation according to ICRP 60, b Calculation according to ICRP 103 
Table 7: KAP-normalized equivalent dose (mSv/Gy∙cm2) as a function of tube voltage and angulations during cardiac interventional procedures.
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Gy∙cm2), but are in general in good agreement [27]. Any differences 
may be attributed to the different phantoms and energy spectra used 
for the simulations. The KAP-normalized effective doses estimated in 
this work according to ICRP 103 could not be compared, as to the best 
of our knowledge, no previous publication estimate effective dose for 
cardiac procedures according to ICRP 103. 
Effective doses for a typical (as previously described) CA and PCI 
procedure are presented in table 10. Dose calculations were performed 
for both ICRP 60 and 103. The KAP-normalized effective doses for 80 
kV were averaged to respect the change in the tube angulation during 
an actual procedure. The mean KAP-normalized E values for ICRP 
60 and 103 were found 0.12 and 0.14 mSv/Gy∙cm2, respectively. This 
difference is quite small and may be attributed mainly to the increase 
of the breast weighting factor. The KAP values from tables 4 and 5 were 
used to calculate E, resulting to a range from 0.2 to 48.3 mSv for CA 
procedures and 1.2 to 33.1 mSv for PCI procedures. Effective doses in 
bibliography ranged between 0.3 to 15.8 mSv for a CA procedure and 
0.9 to 44.7 mSv for a PCI procedure [30]. These wide ranges in patient 
doses may be attributed to the procedure complexity (due to patient 
anatomy, physician experience, etc.) as well as the different conversion 
coefficients used for the estimation of the effective dose.
Effective risk
Organ doses for typical CA and PCI procedures (Table 8) were 
used to estimate the corresponding risks, according to BEIR VII. Risks 
for cancer incidence per 100,000 persons are presented in table 11 as a 
CA PCI
Brain 1.15E-02 2.04E-02
Breast 9.37E+00 1.67E+01
Bone marrow (red) 1.18E+01 2.09E+01
Bone surface 4.07E-02 7.25E-02
Colon 1.91E-01 3.39E-01
Oesophagus 8.08E+00 1.44E+01
Gonads 5.44E-03 9.67E-03
Liver 1.03E+00 1.82E+00
Lung 1.77E+01 3.16E+01
Salivary glands 1.74E-01 3.10E-01
Skin 5.77E+00 1.03E+01
Stomach 5.85E-01 1.04E+00
Thyroid 7.23E-01 1.29E+00
Urinary bladder 1.41E-03 2.52E-03
Remainder organs 3.72E+01 6.61E+01
Table 8: Equivalent organ doses (mSv) for a typical CA and PCI procedure (the 
colon and remainder organ dose estimations were based on ICRP 103).
Tube angulation kVp EKAP - ICRP 60 EKAP - ICRP 103 ICRP 103/ICRP60 
PA 70 0.10 0.11 1.10
80 0.13 0.14 1.08
90 0.15 0.17 1.13
RAO30 70 0.10 0.11 1.10
80 0.12 0.14 1.17
90 0.14 0.16 1.14
RAO30/CAD20 70 0.09 0.10 1.11
80 0.11 0.12 1.09
90 0.13 0.14 1.08
LLAT 70 0.14 0.16 1.14
80 0.17 0.19 1.12
90 0.19 0.22 1.16
LAO10 70 0.10 0.11 1.10
80 0.13 0.14 1.08
90 0.15 0.17 1.13
LAO10/CRA10 70 0.10 0.11 1.10
80 0.13 0.14 1.08
90 0.15 0.17 1.13
LAO60 70 0.05 0.06 1.20
80 0.06 0.07 1.17
90 0.08 0.09 1.13
LAO60/CRA20 70 0.06 0.06 1.00
80 0.07 0.08 1.14
90 0.09 0.10 1.11
Table 9:  KAP-normalized effective dose (mSv/Gy∙cm2) as a function of tube voltage 
and source angulations during cardiac interventional procedures.
E (mSv) Mean Standard 
deviation
Range 25th  
percentile
50th 
percentile
75th
 percentile
ICRP 60
CA 4.5 6.5 0.2 - 48.3 1.7 3.0 4.7
PCI 8.0 5.3 1.2 - 33.1 4.4 6.7 9.9
ICRP103
CA 5.0 7.3 0.3 - 53.9 1.9 3.3 5.2
PCI 8.9 5.9 1.3 - 36.9 4.9 7.4 11.1
Table 10: Effective dose estimation for a typical CA and PCI procedure.
100
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Age at exposure
R
Female
Male
Figure 3: Cancer incidence for a typical CA procedure, as a function of age 
and sex.
CA PCI
Age at 
exposure
30 40 50 60 70 80 30 40 50 60 70 80
Male
Colon 0 0 0 0 0 0 1 1 1 1 0 0
Lung 13 13 13 11 8 4 23 23 22 20 14 8
Other 4 3 3 2 1 0 7 6 5 3 2 1
All solid 18 17 16 14 10 5 32 31 29 24 17 9
Leukaemia 9 9 9 9 8 5 16 16 16 16 14 9
R 27 26 25 22 18 10 48 47 45 40 31 18
Female
Lung 56 55 53 46 34 18 99 98 94 82 60 31
Breast 24 13 7 3 1 0 42 24 12 5 2 1
Other 11 10 8 6 4 2 20 18 14 11 7 3
Thyroid 0 0 0 0 0 0 1 0 0 0 0 0
All solid 91 79 68 55 39 20 163 140 121 98 69 35
Leukaemia 8 8 8 7 6 5 14 14 14 13 12 8
R 99 87 76 63 45 24 177 154 135 111 81 44
Table 11: Cancer incidence per 100,000 typical CA and PCI procedures according 
to age and sex.
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function of age and sex for both procedures. In this table11, the risks 
for lungs, breast, colon and leukaemia are provided. Risks for organs, 
such as stomach, liver, urinary bladder, and prostate were found to 
be very low; thus, not provided in the Table. The estimated risks for 
“other” were dominated by oesophagus cancer. R was estimated for 
different age and sex and is provided in the Table. R simply represents 
the total risk of cancer incidence or mortality. Cancer risks during 
cardiac procedures are dominated by lung and breast cancer. 
Figure 3 illustrates the effective risk for incidence as a function 
of age and sex for a typical CA procedure. R is in general greater at 
younger ages. This may be seen in the figure, where the risk for cancer 
incidence is five times greater at the age of 30 than that at the age 
of 70. Women are more radiation-sensitive than men. Figure 3 shows 
that R for a woman is two to five times greater than that of a man 
who undergoes the same cardiac procedure at the same age, with 
the difference being more intense at younger ages. This difference is 
mainly due to the breast and lung cancer risks.
Comparison of effective dose with effective risk
According to the ICRP [2,31], the purposes of E in radiation 
protection for occupational workers and general public are the 
exposure limitation and prospective dose assessment for optimization 
and the retrospective dose assessment for demonstrating compliance 
with dose limits, or for comparing with dose constraints or reference 
levels. ICRP accepts the use of E for medical procedures in order 
to compare the relative risk i) among different procedures, ii) of 
similar procedures in different hospitals or iii) when using different 
technologies for the same procedure [31]. However, its use involves a 
number of assumptions and limitations. Firstly, the tissue weighting 
factors for the calculation of E are derived by the risks of cancer 
incidence, cancer mortality, life shortening and hereditary risks. 
These risks cannot be combined in one number, as they are rather 
irrelevant to each other [16]. Moreover, E has been widely used to 
estimate patient risks Borras et al. [10], as it can be easily converted 
into an approximate radiation risk, using a risk of fatal cancer of 5% 
per Sv averaged over the whole population [1,2]. The estimation of 
excess lifetime risk of developing cancer due to a radiation exposure 
is more reasonable to be based only on cancer risks. Therefore, the 
use of R seems more appropriate for such calculations. Some attention 
should be paid at this point. The obtained results should only be used 
to compare the relative risk for examinations involving radiation 
exposure and not to predict number of cancers caused by a medical 
procedure. Cancer risk estimations for the individual patient is 
currently impossible due to different patient anatomy which cannot 
be simulated by the average phantoms, genetic susceptibility to 
cancer, uncertainties in cancer risk factors, etc.
Secondly, E is defined to be age- and sex- independent. This 
means that E does not take into account the age at exposure, although 
radiation risks are higher for paediatric and young patients than for 
adults and the fact that women are more radiation-sensitive than 
men. The most important advantage of R is that it takes into account 
different radiation sensitivities among ages and between male and 
female patients. Our calculations showed that for a typical cardiac 
procedure the risk of cancer incidence for a 30-year-old male is five 
times higher than a seventy-year-old and that the cancer incidence 
risk for a female patient is two times higher than the risk of a male 
patient (Figure 3). Figure 4 shows the dependence of E and R on 
radiation exposure. The KAP goes up to 400, which is the maximum 
KAP value found in our study. Both E and R increase with the increase 
of the KAP. While E remains stable for all ages, R decreases with patient 
age. The risk is higher at younger ages (shown in red in Figure 4b). 
Thirdly, the use of E may lead to confusion, as both equivalent 
organ dose and effective dose, which is the weighted sum of equivalent 
doses, are measured in Sv. The unit of R is a number of induced cancers 
per 100,000 procedures. This may eliminate the confusion between 
organ dose and risk. Comprehension and awareness of radiation 
risks is particularly important as it allows physicians to balance risks 
with benefits for each patient. As already discussed, R may be used to 
estimate the number of induced cancers by medical exposure, while 
the purpose of the radiation protection is to provide physicians with 
a way to estimate radiation exposure in order to protect the patient. 
A wrong interpretation of the results that lead to fear and avoidance 
of medical exposure is as wrong as the ignorance of potential risks. 
Referring physicians should understand radiation risks, and be able 
to explain to patients the potential risks and help them take the right 
decision. The correct use of radiation protection quantities is useful for 
the radiation protection of the patient and the good communication 
between medical physicists, physicians and patients. This becomes 
more urgent nowadays because the use of radiation in medicine 
is expanding [4] and modern medicine demands shared decision 
making between physicians and patients [17]. Therefore, risks due 
to ionizing radiation have to be put into perspective with other risks 
(in-hospital complications, false positive or negative results, etc.) and 
communicated to the patient to get his/her consent. 
Examining the practical aspects of R, we found that calculating 
R was as complicated as calculating E. The results for R, depending 
on patient sex and age, may be considered as much more complex 
and disturbing than the effective dose where only one number is 
acquired. Although this may be considered as a limitation of R, it 
provides important information about patient risk and may help 
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Figure 4: (a) Effective dose (mSv) and (b) cancer incidence risk per 100,000 
cardiac procedures (calculations based on female risks) as a function of age 
(y) and KAP (Gy∙cm
2).
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for deep understanding and active reduction in patient exposure. 
Changing from E to R is difficult, as E has been extensively used for 
the estimation of medical exposures. However, we believe that R is 
currently the most accurate method of estimating radiation risks. 
More studies should be performed on how physicians and radiation 
protection experts perceive the use of R. 
Limitations of the study
The first limitation of this study is that the patient study did not 
allow us to estimate the KAP for different angulations of the tube. 
However, our approximation to consider the contribution of the 
different angulations as equal may be considered satisfactory in order 
to simulate a typical cardiac procedure. Another source of error in 
the estimation of the organ dose is related to variations of organ 
location and size from the average. Nevertheless, the use of voxelized 
anthropomorphic phantoms that represent the average patient is the 
most realistic approach to the issue. Finally, the linear non-threshold 
model was used to derive risks for low doses from epidemiologic 
studies on effects of individuals exposed to high levels of ionizing 
radiation, such as atomic bomb survivors, patients exposed to 
radiation for medical treatments and animal experiments. This model 
has been thoroughly argued. However, the main radiation protection 
organizations and advisory authorities assume that low-radiation 
doses are associated with hazard risks [1,4,8] and this assumption was 
also adopted in this study.
Conclusion
Cardiac procedures can result in considerable radiation doses 
to the patient, even when performed with modern fluoroscopic 
equipment. The patient may be exposed to even higher radiation doses 
due to extended exposure times affected by his clinical condition. 
Cancer risks cannot be neglected, especially for relatively young 
patients. Radiation protection needs to be better communicated 
in order to be well accomplished. Monte Carlo simulations were 
performed to simulate two typical cardiac procedures. Normalized 
dose data were derived for the estimation of organ doses. Data 
provided in this study allow organ dose estimation, regardless of the 
operating parameters and equipment used. Equivalent organ doses 
were estimated and the effective dose was calculated using both 
ICRP recommendations 60 and 103. The differences in effective dose 
according the two recommendations were found small. Effective dose 
allows comparisons of the radiation doses among different medical 
procedures; however it appears to be rather inappropriate for risk 
communication among specialists and non-specialists. Moreover, 
effective dose suppresses the effect of age and sex on radiation risk. 
On the other hand, the effective risk is a straightforward method 
to communicate and understand radiation risks. We believe that 
the effective risk is the most accurate method, currently available, 
to estimate radiation risks. Work still needs to be done, however, to 
examine how physicians perceive the use of effective risk and the 
impact of its use in the day-to-day practice.
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